EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average “Moderate Buy” Recommendation From Brokerages

Shares of EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT – Get a rating) received a consensus “moderate buy” recommendation from the five analysts who cover the company, reports MarketBeat.com. One analyst rated the stock with a hold recommendation and three gave the company a buy recommendation. The 12-month average target price among brokers who have reported on the stock in the past year is $27.00.

Several brokerages have recently commented on EYPT. StockNews.com began covering EyePoint Pharmaceuticals shares in a report on Wednesday. They issued a “hold” rating on the stock. Chardan Capital began covering EyePoint Pharmaceuticals shares in a report on Thursday, July 7. They issued a “buy” rating and a price target of $21.00 on the stock. Finally, HC Wainwright raised its price target on EyePoint Pharmaceuticals shares from $24.00 to $25.00 in a Thursday, August 4 report.

Institutional investors weigh in on EyePoint Pharmaceuticals

Several large investors have recently increased or reduced their stake in EYPT. Zurcher Kantonalbank Zurich Cantonalbank acquired a new equity stake in EyePoint Pharmaceuticals in Q1 for approximately $30,000. Amalgamated Bank purchased a new equity stake in EyePoint Pharmaceuticals in Q1 worth approximately $31,000. Cubist Systematic Strategies LLC increased its position in EyePoint Pharmaceuticals shares by 46.6% in the second quarter. Cubist Systematic Strategies LLC now owns 6,600 shares of the company valued at $52,000 after purchasing 2,099 additional shares in the last quarter. Royal Bank of Canada increased its position in EyePoint Pharmaceuticals shares by 31.9% in the first quarter. Royal Bank of Canada now owns 7,934 shares of the company valued at $97,000 after buying 1,918 more shares in the last quarter. Finally, Principal Financial Group Inc. purchased a new stake in EyePoint Pharmaceuticals stock in Q2 valued at approximately $97,000. 88.65% of the shares are held by hedge funds and other institutional investors.

Performance of EyePoint Pharmaceuticals shares

NASDAQ:EYPT opened at $5.60 on Friday. The company has a debt ratio of 0.19, a current ratio of 6.17 and a quick ratio of 6.07. The company has a market capitalization of $190.80 million, a price-earnings ratio of -2.49 and a beta of 1.28. The company’s 50-day moving average is $8.66 and its two-hundred-day moving average is $9.47. EyePoint Pharmaceuticals has a 1-year low of $5.31 and a 1-year high of $21.50.

EyePoint Pharmaceuticals (NASDAQ:EYPT – Get a rating) last released its quarterly earnings data on Wednesday, August 3. The company reported ($0.52) EPS for the quarter, beating the consensus estimate of ($0.57) by $0.05. EyePoint Pharmaceuticals had a negative net margin of 186.14% and a negative return on equity of 50.36%. The company posted revenue of $11.57 million for the quarter, versus analyst estimates of $11.27 million. Analysts expect EyePoint Pharmaceuticals to post year-to-date EPS of -2.43.

About EyePoint Pharmaceuticals

(Get a rating)

EyePoint Pharmaceuticals, Inc, a pharmaceutical company, develops and markets ophthalmic products for the treatment of eye diseases in the United States, China and the United Kingdom. The company offers ILUVIEN, a sustained-release injectable micro-insert for the treatment of diabetic macular edema; YUTIQ, an intravitreal fluocinolone acetonide implant for intravitreal injection for the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye; and DEXYCU, an intraocular suspension of dexamethasone, for the treatment of postoperative eye inflammation, including treatment after cataract surgery.

See also

This instant news alert was powered by MarketBeat’s storytelling science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Before you consider EyePoint Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and EyePoint Pharmaceuticals was not on the list.

While EyePoint Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the five actions here

Comments are closed.